TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))

Docket No. 41 1849.16102-A CIP 2

۱ به	Serial No.	Filing Date	Examiner	Group Art Unit
B1	09/5208856	March 7, 2000	Unknown	3731
tie:	Biocompatible	Material Composition Adaptable to	Diverse Therapeutic Indicati	RECEIVED.
	·	Δ	ddress to:	TECHNOLOGY 2 1 20
		Assistant Com	missioner for Patents ton, D.C. 20231	JUN 0 4 2001
		ECH CENTED 1600/0000		
X	of a national a CFR 1.491 in	on Disclosure Statement submitted application; within three months of a an international application; or be ever event occurs last.	the date of entry of the nation	nal stage as set forth in 37
		37 C	FR 1.97(c)	
	of a national a international a	37 Con Disclosure Statement submitted application, or the date of entry of application; or after the mailing dout before the mailing date of either	therewith is being filed after the national stage as set for ate of a first Office Action	rth in 37 CFR 1.491 in an
	of a national a international a	on Disclosure Statement submitted application, or the date of entry of application; or after the mailing d	therewith is being filed after the national stage as set for ate of a first Office Action	rth in 37 CFR 1.491 in an
	of a national a international a occurred last b	on Disclosure Statement submitted application, or the date of entry of application; or after the mailing dout before the mailing date of either	therewith is being filed after the national stage as set for ate of a first Office Action ::	rth in 37 CFR 1.491 in an on the merits, whichever
	of a national a international a occurred last b	on Disclosure Statement submitted application, or the date of entry of application; or after the mailing dout before the mailing date of either a Final Action under 37 CFR 1.1 a Notice of Allowance under 37 CFR 1.1	therewith is being filed after the national stage as set for ate of a first Office Action 13, or CFR 1.311,	rth in 37 CFR 1.491 in an on the merits, whichever
	of a national a international a occurred last b	on Disclosure Statement submitted application, or the date of entry of application; or after the mailing dout before the mailing date of either a Final Action under 37 CFR 1.1 a Notice of Allowance under 37 CFR 1.1	therewith is being filed after the national stage as set for ate of a first Office Action 13, or CFR 1.311,	rth in 37 CFR 1.491 in an on the merits, whichever
	of a national a international a occurred last b	on Disclosure Statement submitted application, or the date of entry of application; or after the mailing dout before the mailing date of either a Final Action under 37 CFR 1.1 a Notice of Allowance under 37 CFR 1.1	therewith is being filed after the national stage as set for ate of a first Office Action 13, or CFR 1.311,	rth in 37 CFR 1.491 in an on the merits, whichever
	of a national a international a occurred last b	on Disclosure Statement submitted application, or the date of entry of application; or after the mailing dout before the mailing date of either a Final Action under 37 CFR 1.1 a Notice of Allowance under 37 dever occurs first.	therewith is being filed after the national stage as set for ate of a first Office Action 13, or CFR 1.311,	rth in 37 CFR 1.491 in an on the merits, whichever

X

(Under 37 CFR 1.97(b) or 1.97	
In Re-Application Of: Olexander Hnojewyj et al.	
Serial No. Filing Date	Examiner Group Art Unit
PRADE March 7, 2000	
Title: Biocompatible Material Composition Adaptable to	Diverse Therapeutic Indications
· ·	Diverse Therapeutic Indications MAY 2 1 2001 ent of Fee
	ent of Fee o pay the fee set forth in 37 CFR 1.17(p))
as described below. A duplicate copy of this sheet Charge the amount of Credit any overpayment. Charge any additional fee required. Certificate of Transmission by Facsimile* I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. On. (Date)	ched. to charge and credit Deposit Account No. 06-2360 TECH CENTER 1600/2 Certificate of Mailing by First Class Mail I certify that this document and fee is being deposited on May 14, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.
Signature	Signature of Person Mailing Correspondence
Typed or Printed Name of Person Signing Certificate	Mary Szollar Typed or Printed Name of Person Mailing Correspondence
*This certificate may only be used if paying by deposit account Signature Daniel D. Ryan, Reg. No. 29,243 Ryan Kromholz & Manion, S.C. P.O. Box 26618 Milwaukee, Wisconsin 53226-0618 (262) 783-1300	Dated: May 14, 2001 RECEIVED MAY 30 2001

cc:

Copyright 1996 Legalsoft

P10A/REV01